Barclays Issues Pessimistic Forecast for Sotera Health (NASDAQ:SHC) Stock Price

Sotera Health (NASDAQ:SHC - Get Free Report) had its price target cut by analysts at Barclays from $15.00 to $13.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has an "overweight" rating on the stock. Barclays's price objective would indicate a potential upside of 14.88% from the stock's previous close.

A number of other analysts have also issued reports on the stock. Wall Street Zen lowered shares of Sotera Health from a "buy" rating to a "hold" rating in a research report on Saturday, June 7th. Piper Sandler decreased their price objective on Sotera Health from $15.00 to $13.00 and set a "neutral" rating on the stock in a report on Wednesday, April 23rd. Finally, The Goldman Sachs Group upgraded Sotera Health from a "neutral" rating to a "buy" rating and upped their target price for the company from $14.00 to $17.00 in a research note on Monday, May 5th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $16.00.

Sotera Health Price Performance

Shares of NASDAQ SHC traded down $0.04 during trading on Tuesday, reaching $11.32. The company had a trading volume of 383,950 shares, compared to its average volume of 1,202,873. The company has a current ratio of 2.46, a quick ratio of 2.19 and a debt-to-equity ratio of 5.55. Sotera Health has a twelve month low of $9.53 and a twelve month high of $17.08. The stock has a 50-day moving average price of $11.98 and a two-hundred day moving average price of $12.40. The stock has a market capitalization of $3.21 billion, a PE ratio of 141.47 and a beta of 1.87.

Sotera Health (NASDAQ:SHC - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.02. Sotera Health had a net margin of 2.24% and a return on equity of 41.08%. The firm had revenue of $254.52 million during the quarter, compared to the consensus estimate of $245.56 million. During the same quarter in the previous year, the company posted $0.13 EPS. The firm's revenue for the quarter was up 2.6% on a year-over-year basis. As a group, sell-side analysts predict that Sotera Health will post 0.61 earnings per share for the current year.

Hedge Funds Weigh In On Sotera Health

A number of hedge funds have recently made changes to their positions in SHC. Vanguard Group Inc. raised its position in shares of Sotera Health by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 14,923,546 shares of the company's stock worth $204,154,000 after buying an additional 173,341 shares during the period. Sculptor Capital LP lifted its stake in shares of Sotera Health by 80.8% in the 1st quarter. Sculptor Capital LP now owns 9,037,511 shares of the company's stock valued at $105,377,000 after purchasing an additional 4,037,511 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in shares of Sotera Health by 5.9% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 8,045,502 shares of the company's stock valued at $93,811,000 after purchasing an additional 450,761 shares in the last quarter. TPG GP A LLC purchased a new stake in shares of Sotera Health during the 1st quarter worth about $79,126,000. Finally, Two Seas Capital LP increased its position in Sotera Health by 14.7% during the 1st quarter. Two Seas Capital LP now owns 3,321,136 shares of the company's stock worth $38,724,000 after purchasing an additional 425,000 shares in the last quarter. Institutional investors and hedge funds own 91.03% of the company's stock.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.